论文部分内容阅读
目的探讨曲美他嗪治疗缺血性心肌病心力衰竭的临床效果。方法选择64例缺血性心肌病心力衰竭患者作为研究对象,随机分为对照组和观察组,所有患者均给予常规治疗,观察组患者在常规治疗的基础上另外口服曲美他嗪,对比临床治疗效果。结果对照组总有效率为71.88%,观察组为93.75%,差异有统计学意义(P<0.05)。患者在治疗后各项检测指标均有所改善,治疗前后两组左室收缩末期容积、左室短轴缩短率、每搏输出量、左心射血分数检测值比较差异均有统计学意义(P<0.05)。结论对于缺血性心肌病心力衰竭患者,进行曲美他嗪治疗疗效显著,可改善患者心功能状态,进一步提高患者生存质量,值得临床应用。
Objective To investigate the clinical efficacy of trimetazidine in the treatment of heart failure with ischemic cardiomyopathy. Methods 64 cases of ischemic cardiomyopathy patients with heart failure were randomly divided into control group and observation group. All patients were given routine treatment. Patients in observation group were given oral trimetazidine on the basis of routine treatment, treatment effect. Results The total effective rate was 71.88% in the control group and 93.75% in the observation group, the difference was statistically significant (P <0.05). Patients in the treatment of various indicators have improved after treatment, before and after treatment, left ventricular end-systolic volume, shortening of left ventricular short axis, stroke volume, left ventricular ejection fraction scores were statistically significant differences ( P <0.05). Conclusion For patients with heart failure with ischemic cardiomyopathy, trimetazidine treatment has a significant effect, which can improve the cardiac function and further improve the quality of life of patients, which is worthy of clinical application.